[{"orgOrder":0,"company":"Philogen","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Onfekafusp Alpha","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Philogen \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Philogen","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Bifikafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Philogen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"Bifikafusp Alpha","moa":"||Angiogenesis","graph1":"Oncology","graph2":"Undisclosed","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Philogen \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Philogen \/ Merck & Co"},{"orgOrder":0,"company":"Philogen","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Bifikafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Doxorubicin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"University Hospital Z\u00fcrich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Fibromun","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ University Hospital Z\u00fcrich","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ University Hospital Z\u00fcrich"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Bifikafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bifikafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bifikafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bifikafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bifikafusp Alpha","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Fibromun","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Philogen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Plastics Recycling EU
Not Confirmed
Plastics Recycling EU
Not Confirmed

Lead Product(s) : Bifikafusp Alpha,L19TNF

Therapeutic Area : Oncology

Study Phase : Phase III

Sponsor : Sun Pharmaceutical Industries Limited

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Announced the filing of a marketing authorisation application with the European Medicines Agency for Nidlegy, an investigational neoadjuvant therapy, for locally advanced, fully resectable melanoma.

Product Name : Nidlegy

Product Type : Protein

Upfront Cash : Inapplicable

April 06, 2024

Lead Product(s) : Bifikafusp Alpha,L19TNF

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Sun Pharmaceutical Industries Limited

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

02

Plastics Recycling EU
Not Confirmed
Plastics Recycling EU
Not Confirmed

Details : L19TNF (onfekafusp alfa), a homotrimer peptide fused to human TNF, is being evaluated with doxorubicin for first-line treatment of advanced or metastatic soft tissue sarcoma.

Product Name : Fibromun

Product Type : Other Large Molecule

Upfront Cash : Inapplicable

February 20, 2024

Lead Product(s) : Onfekafusp Alpha,Doxorubicin Hydrochloride

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

03

Plastics Recycling EU
Not Confirmed
Plastics Recycling EU
Not Confirmed

Lead Product(s) : Onfekafusp Alpha

Therapeutic Area : Oncology

Study Phase : Phase III

Sponsor : Sun Pharmaceutical Industries Limited

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Details : The agreement aims for the commercialisation of Fibromun (onfekafusp alfa), being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma.

Product Name : Fibromun

Product Type : Other Large Molecule

Upfront Cash : Undisclosed

January 10, 2024

Lead Product(s) : Onfekafusp Alpha

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Sun Pharmaceutical Industries Limited

Deal Size : Undisclosed

Deal Type : Licensing Agreement

blank

04

Plastics Recycling EU
Not Confirmed
Plastics Recycling EU
Not Confirmed

Details : Nidlegy (bifikafusp alfa & onfekafusp alfa) is designed for the treatment of skin cancer. It consists of two active ingredients, L19IL2 and L19TNF which are manufactured independently, and which are mixed prior to intralesional administration.

Product Name : Nidlegy

Product Type : Protein

Upfront Cash : Inapplicable

October 16, 2023

Lead Product(s) : Bifikafusp Alpha,Onfekafusp Alpha

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

05

Plastics Recycling EU
Not Confirmed
Plastics Recycling EU
Not Confirmed

Lead Product(s) : Bifikafusp Alpha,Onfekafusp Alpha

Therapeutic Area : Oncology

Study Phase : Phase III

Sponsor : Sun Pharmaceutical Industries Limited

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Details : Under the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy (bifikafusp alfa), a new anti-cancer biopharmaceutical, being developed by Philogen for melanoma and non-melanoma skin cancers, in the territories of Europe, Australia an...

Product Name : Nidlegy

Product Type : Protein

Upfront Cash : Undisclosed

May 30, 2023

Lead Product(s) : Bifikafusp Alpha,Onfekafusp Alpha

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Sun Pharmaceutical Industries Limited

Deal Size : Undisclosed

Deal Type : Licensing Agreement

blank

06

Plastics Recycling EU
Not Confirmed
Plastics Recycling EU
Not Confirmed

Details : L19TNF is a fully-human immunomodulatory product consisting of the L19 antibody and TNF. The L19 antibody is specific to the EDB domain of fibronectin and mediates selective localization of TNF to the site of disease while sparing healthy organs.

Product Name : L19TNF

Product Type : Protein

Upfront Cash : Inapplicable

May 24, 2023

Lead Product(s) : Fibromun,Lomustine

Therapeutic Area : Oncology

Highest Development Status : Phase I/ Phase II

Sponsor : University Hospital Zürich

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

07

Plastics Recycling EU
Not Confirmed
Plastics Recycling EU
Not Confirmed

Details : Under the supply agreement, MSD provides their anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), to be evaluated in combination with Philogen's immunocytokines L19IL2, L19TNF, and Nidlegy (bifikafusp alfa) in a randomized Phase II clinical trial in unresect...

Product Name : Nidlegy

Product Type : Protein

Upfront Cash : Undisclosed

January 06, 2023

Lead Product(s) : Bifikafusp Alpha,Onfekafusp Alpha

Therapeutic Area : Oncology

Highest Development Status : Undisclosed

Sponsor : Merck & Co

Deal Size : Undisclosed

Deal Type : Collaboration

blank

08

Plastics Recycling EU
Not Confirmed
Plastics Recycling EU
Not Confirmed

Details : Nidlegy (bifikafusp alfa) is combination of the immunocytokines L19IL2 and L19TNF, which is being developed as intralesional treatment for patients with advanced locoregional melanoma and non-melanoma skin cancers.

Product Name : Nidlegy

Product Type : Protein

Upfront Cash : Inapplicable

July 25, 2022

Lead Product(s) : Bifikafusp Alpha,Onfekafusp Alpha

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

09

Plastics Recycling EU
Not Confirmed
Plastics Recycling EU
Not Confirmed

Details : Nidlegy™, the combination of the two active principles bifikafusp alfa (L19IL2) and onfekafusp alfa (L19TNF), has already shown promising results in the intralesional treatment of patients with advanced melanoma and in BCC and cSCC in an ongoing Phase ...

Product Name : Nidlegy

Product Type : Protein

Upfront Cash : Inapplicable

February 17, 2022

Lead Product(s) : Bifikafusp Alpha,Onfekafusp Alpha

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

10

Plastics Recycling EU
Not Confirmed
Plastics Recycling EU
Not Confirmed

Details : Nidlegy, as a neoadjuvant was found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated in PIVOTAL phase III trial in melanoma patients with locally advanced, fully resectable metastatic cancer.

Product Name : Nidlegy

Product Type : Protein

Upfront Cash : Inapplicable

January 13, 2022

Lead Product(s) : Bifikafusp Alpha,Onfekafusp Alpha

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank